- Overcoming Low Selectivity and High Toxicity Challenges of Traditional Chemotherapy
- Enhancing Cytotoxic Effect and Targeting Ability
- Promoting Individualized Precision Treatment
Antibody drug conjugates (ADCs) have the potential to revolutionize conventional cancer treatment. They comprise of monoclonal antibodies that selectively deliver potent cytotoxic drugs. Each component of the ADC must be optimized to fully realize the goal of a targeted therapy with improved efficacy and tolerability. Advancements over the past several decades have led to a new generation of ADCs with balanced stability and highly potent cytotoxic agents. Although challenges remain, recent clinical successes have generated intense interest in this therapeutic class. World BI’s The ABC of ADCs discusses the characterization challenges of these ADCs and also their role in targeted tumor therapy.
Meet our Professionals
Strategic and Technical Advisor Chief Data and AI Office
Director – Antibody Engineering (Bispecifics and CAR-T)
The Janssen Pharmaceutical Companies of Johnson & Johnson
Chief Drug Hunter & President
Global Head of Oncology Discovery Pharmacology
Roche Innovation Center Zurich
Head of Artificial Intelligence
Milner Therapeutics Institute University of Cambridge
Vast number of different speeches
Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the event's website and more... If you search for a conference or exhibition in areas such as Industry and manufacturing, Health and medicine, Technology and IT, Business and finance, sciences, education, services (banking, insurance, tourism, Hospitality and more), government, environment, life style and arts, you'll find it in Clocate.com.